A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis | BMC Cancer | Full Text

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis | BMC Cancer | Full Text

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the...

Authors:Jin Hong, Jiahui Huang, Lili Shen, Siji Zhu, Weiqi Gao, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen and Kunwei Shen

Citation:BMC Cancer 2020 20:663

Content type:Research article

 

Published on: 16 July 2020

• ViewFull Text
 
• ViewPDF